MMR Vaccines

MMR Vaccines Market Outlook

The global MMR vaccines market is projected to reach USD 8.23 billion by 2035, growing at a CAGR of approximately 5.2% from 2025 to 2035. This growth is primarily driven by an increase in vaccination awareness, rising incidence of measles, mumps, and rubella outbreaks, and government initiatives to promote immunization programs. Furthermore, advancements in vaccine manufacturing technology and comprehensive public health campaigns are expected to contribute significantly to market growth. Continuous research and development efforts to enhance vaccine efficacy and safety are also bolstering the market. Additionally, the rising number of healthcare facilities and access to vaccinations worldwide are further supporting the expansion of the MMR vaccines market.

Growth Factor of the Market

One of the main growth factors driving the MMR vaccines market is the increasing global incidence of measles, which has highlighted the importance of vaccination programs in preventing outbreaks. Public health authorities and governments are ramping up their vaccination campaigns, particularly in developing countries, where healthcare access is limited. Moreover, the growing recognition of the significance of herd immunity has led to widespread advocacy for MMR vaccinations, further propelling market growth. The rise in disposable income and healthcare expenditure in emerging economies also contributes to increased vaccination rates, as families can afford the necessary healthcare services. Additionally, partnerships between governments and non-profit organizations for immunization initiatives are expected to enhance vaccine availability and distribution, thereby stimulating market growth.

Key Highlights of the Market

• Increasing government initiatives and awareness campaigns are enhancing vaccination rates globally.
• Rising incidence of measles, mumps, and rubella outbreaks is driving demand for MMR vaccines.
• Advancements in vaccine technology are improving safety and efficacy profiles.
• Growing healthcare infrastructure in emerging economies is facilitating vaccine accessibility.
• Partnerships among healthcare stakeholders are supporting robust vaccination programs.

By Product Type

Measles-Mumps-Rubella Vaccine:

The Measles-Mumps-Rubella (MMR) vaccine is a combination vaccine designed to protect individuals against three highly contagious viral diseases: measles, mumps, and rubella. This vaccine is often administered during childhood as part of standard immunization schedules across many countries. It has been found to be highly effective in eliciting immune responses, allowing for population immunity when coverage rates are sufficiently high. The increased focus on eradicating these diseases globally has led to a consistent demand for the MMR vaccine, which plays a crucial role in public health initiatives aimed at preventing outbreaks.

Measles-Rubella Vaccine:

The Measles-Rubella vaccine is specifically aimed at preventing measles and rubella, excluding mumps from its protective coverage. This variant of the MMR vaccine is utilized in various regions where mumps incidence is low but where measles and rubella continue to pose significant health threats. The adoption of this vaccine is particularly prevalent in mass immunization campaigns targeting young children and women of childbearing age, thereby contributing to a decline in both measles and rubella cases globally. Its targeted approach allows for more tailored immunization strategies in different populations.

Measles-Mumps Vaccine:

The Measles-Mumps vaccine is designed to protect against measles and mumps specifically. This vaccine is often administered where rubella is less of a concern, and it helps to prevent outbreaks of measles and mumps in populations at risk. The relevance of the Measles-Mumps vaccine has been underscored by recent outbreaks, making it an essential tool for public health officials. As vaccination campaigns evolve to address specific epidemiological needs, the demand for this vaccine persists, particularly in regions experiencing higher incidences of these two diseases.

Mumps-Rubella Vaccine:

The Mumps-Rubella vaccine provides immunity against both mumps and rubella but does not protect against measles. This vaccine is particularly useful in specific demographic groups or geographic areas where mumps and rubella pose a higher health risk. Its administration is often coupled with public health campaigns focusing on maternal health, thereby safeguarding against congenital rubella syndrome. As health authorities aim to reduce the burden of these preventable diseases, the Mumps-Rubella vaccine continues to be integral within targeted immunization strategies.

Others:

This category includes various formulations and combination vaccines developed to address specific regional health needs or demographic groups. These might include experimental vaccines or those that utilize innovative delivery methods, which could enhance the overall effectiveness of immunization campaigns. The ongoing research and development in the vaccine landscape are leading to the emergence of these alternatives, allowing public health officials greater flexibility in their immunization strategies to combat measles, mumps, and rubella effectively.

By Application

Pediatrics:

The pediatric segment is the largest application area for MMR vaccines, as immunization against measles, mumps, and rubella is a critical component of childhood vaccination programs worldwide. Vaccination is typically administered between 12 to 15 months of age, with a booster dose given between 4 to 6 years. Due to the vulnerability of children to these diseases and the potential for severe complications, health organizations prioritize pediatric vaccination efforts. Public health campaigns often focus on educating parents about the benefits of vaccinating children, thus ensuring higher uptake rates and contributing to the overall success of immunization strategies.

Adults:

While MMR vaccination is primarily targeted at children, the adult segment is becoming increasingly important, particularly among individuals who may not have received the vaccine in childhood or those who are at high risk of exposure. This includes adults traveling to areas with ongoing outbreaks, healthcare workers, and individuals in close-contact settings. Awareness among adults regarding the importance of vaccination is growing, driven by rising awareness of disease resurgence. Vaccination recommendations for adults, particularly for those born after 1956 in the United States, are reinforcing the need for booster doses, further expanding this application segment.

Travelers:

As global travel increases, the traveler segment is vital for MMR vaccine applications. Individuals traveling to regions with endemic measles, mumps, or rubella face heightened risks of exposure. Many countries require proof of vaccination for entry, particularly for travel to outbreak-prone areas. Therefore, travelers are increasingly seeking vaccinations prior to their journeys, which is contributing to market growth. Public health advisories emphasizing the importance of MMR vaccination before international travel are also heightening awareness, leading to increased demand for travel-specific vaccination programs.

Healthcare Workers:

Healthcare workers are at a higher risk of exposure to measles, mumps, and rubella, making them a crucial target group for MMR vaccination efforts. Immunization programs focused on healthcare professionals are essential in preventing outbreaks within healthcare settings, where vulnerable populations may be at risk. Many health organizations recommend that healthcare workers ensure their vaccination status is up-to-date, further driving the demand for MMR vaccines within this application segment. This focus reinforces the importance of immunization in maintaining public health safety and protecting both patients and staff in healthcare environments.

Others:

The 'Others' category encompasses various groups and settings where MMR vaccination is relevant but does not fall strictly within the above classifications. This may include populations such as university students, military personnel, or individuals in communal living situations, where the risk of outbreaks can be elevated. Targeted vaccination campaigns directed at these populations are crucial for outbreak prevention and control, reflecting the need for flexible immunization strategies. The inclusion of diverse groups within the vaccination scope illustrates the comprehensive nature of public health initiatives aimed at eradicating these diseases.

By Distribution Channel

Hospitals:

Hospitals play a pivotal role in the distribution of MMR vaccines, serving as primary sites for immunization, especially for children and high-risk populations. They are equipped with the necessary infrastructure to provide vaccinations safely and effectively. Hospitals frequently conduct immunization drives, often collaborating with public health departments to enhance outreach efforts. Additionally, they typically have the expertise and resources to manage any immediate adverse reactions, further assuring patients and their families of the safety of vaccination. The reliance on hospitals for MMR vaccinations remains significant, particularly in more developed healthcare systems.

Clinics:

Clinics, including private healthcare facilities and community health centers, are crucial distribution channels for MMR vaccines, offering convenience and accessibility for patients. They often provide vaccinations as part of routine check-ups or well-child visits, making it easier for families to ensure their children are immunized on schedule. Clinics can also cater to localized needs, providing targeted outreach in communities with lower vaccination rates. The adaptability of clinics to offer vaccinations in various settings contributes significantly to increasing vaccination coverage rates within the population.

Retail Pharmacies:

Retail pharmacies are emerging as important players in the distribution of MMR vaccines, providing a more accessible option for patients seeking immunization. With extended hours and convenient locations, pharmacies enable individuals to receive vaccinations without needing an appointment, increasing overall uptake. The rising trend of pharmacists being authorized to administer vaccines has bolstered the role of retail pharmacies in public health initiatives. This channel is especially appealing for adult vaccinations, allowing adults to easily receive their MMR vaccine as part of their routine pharmacy visit.

Online Pharmacies:

Online pharmacies are gaining traction as alternative distribution channels for vaccinations, particularly in the context of telehealth and digital health solutions. While the administration of the vaccine itself typically requires in-person participation, online pharmacies can facilitate vaccine awareness, education, and appointment scheduling with local providers. The convenience of online access aligns with contemporary consumer behaviors, thereby enhancing overall public engagement with vaccination programs. This channel holds the potential to increase vaccination rates, particularly among tech-savvy populations who prefer utilizing digital platforms for healthcare services.

Others:

The 'Others' distribution channel category includes non-traditional settings and outreach programs aimed at increasing access to MMR vaccines. This may involve mobile vaccination units, community health fairs, schools, and other venues tailored to specific populations. These initiatives are essential for reaching underserved areas, where healthcare access may be limited. By providing vaccines in diverse and convenient locations, public health organizations can improve vaccination coverage and address disparities in immunization rates across different demographic groups.

By Ingredient Type

Live Attenuated Virus:

Live attenuated virus vaccines are foundational to the efficacy of MMR vaccines, providing robust immune responses through the use of weakened forms of the virus. This method effectively stimulates the immune system to develop defenses against measles, mumps, and rubella without causing the diseases themselves. As the primary ingredient in many MMR vaccines, live attenuated viruses are instrumental in achieving long-lasting immunity in vaccinated individuals. The strategic use of live attenuated viruses has been essential in global vaccination efforts, contributing to the decreasing incidence of these diseases in many regions.

Excipients:

Excipients play a critical role in MMR vaccine formulations by serving as stabilizers, preservatives, or adjuvants that enhance the vaccine's efficacy and safety. These ingredients support the stability and effectiveness of the live attenuated viruses during storage and administration. The careful selection and formulation of excipients are vital to ensuring the overall quality and performance of vaccines, thereby impacting the success of immunization programs. Research and development efforts continue to explore new excipients that can further enhance the stability and delivery of vaccines in various settings.

Preservatives:

Preservatives are added to some MMR vaccines to prevent microbial contamination during storage and handling. These ingredients are essential for ensuring the safety and integrity of vaccine formulations, particularly for multi-dose vials. Although many modern vaccines are designed to be preservative-free, particularly in pediatric formulations, the careful consideration of preservatives remains integral in vaccine development. The ongoing discussions regarding the necessity and safety of preservatives in vaccines reflect the complexities of vaccine formulation, emphasizing the importance of maintaining high safety standards.

Stabilizers:

Stabilizers are crucial components in MMR vaccines, helping to maintain the effectiveness of the active ingredients during storage and transit. These ingredients protect the live attenuated viruses from potential degradation due to temperature fluctuations or environmental factors. The presence of stabilizers allows vaccines to remain viable for extended periods, facilitating their distribution to various healthcare settings. Ongoing advancements in stabilizer formulations aim to further improve the resilience and shelf-life of vaccines, which is particularly important in regions with limited cold-chain infrastructure.

Others:

The 'Others' ingredient type category includes various ancillary ingredients that may be utilized in specific vaccine formulations. This may encompass novel adjuvants aimed at enhancing immune response or other supportive materials that contribute to the overall efficacy of the vaccine. Continuous research in vaccine science is exploring innovative ingredients that can further optimize both the safety and effectiveness of MMR vaccines. The incorporation of these ingredients reflects the dynamic nature of vaccine development as researchers strive to improve immunization outcomes worldwide.

By Region

The North America region is a significant market for MMR vaccines, driven by established healthcare infrastructure and strong public health initiatives. The region has witnessed a resurgence of measles cases due to vaccine hesitancy, leading to increased emphasis on vaccination programs. The MMR vaccine is readily available, and extensive educational campaigns have been launched to improve public awareness of the benefits of immunization. The projected CAGR for the North American MMR vaccines market is around 4.5%, reflecting the ongoing efforts to enhance vaccination rates and control outbreaks. The market size in this region is estimated to reach approximately USD 3 billion by 2035, underlining its prominence in the global landscape.

In Europe, the MMR vaccines market is characterized by diverse vaccination policies, leading to varying uptake rates across different countries. The European region has been grappling with outbreaks of measles and rubella, prompting public health authorities to strengthen their vaccination campaigns. Countries with lower immunization rates are focusing on improving access to vaccines and raising awareness, while those with higher rates continue to maintain robust programs. The overall market in Europe is expected to grow at a CAGR of approximately 5.0%, with an estimated market size of USD 2.5 billion by 2035. This growth is essential for addressing public health challenges and ensuring herd immunity within the population.

Opportunities

The MMR vaccines market presents numerous opportunities driven by the increasing global emphasis on vaccination as a fundamental public health strategy. Governments and non-governmental organizations are ramping up efforts to eliminate vaccine-preventable diseases, particularly in regions with historically low immunization coverage. This focus is creating a robust demand for MMR vaccines, particularly in developing countries where outbreaks are prevalent. Additionally, as vaccine hesitancy remains a challenge, targeted educational initiatives and outreach programs can enhance public understanding of the importance of vaccinations, thereby improving uptake rates. Collaborative efforts among stakeholders, including governments, healthcare providers, and pharmaceutical companies, are essential for addressing barriers to vaccination and ensuring equitable access.

Another significant opportunity lies in the advancements in vaccine technology and formulation. Ongoing research and development efforts are exploring innovative vaccine delivery methods, including needle-free injections and combination vaccines that address multiple diseases. Such advancements hold the potential to enhance the acceptability and effectiveness of vaccinations, particularly in populations with lower compliance rates. Furthermore, the integration of digital health technologies, such as mobile health applications for appointment scheduling and vaccine tracking, presents an opportunity to improve patient engagement and streamline vaccination processes. By leveraging technology and innovation, stakeholders can create a more efficient and effective immunization landscape, ultimately leading to improved public health outcomes.

Threats

Despite the promising growth potential in the MMR vaccines market, there are several threats that could impede progress. One of the primary threats is the rise of vaccine misinformation and hesitancy, which has been exacerbated by social media and misinformation campaigns. This skepticism about vaccine safety and efficacy can lead to decreased vaccination rates, making populations vulnerable to outbreaks of measles, mumps, and rubella. Health authorities face significant challenges in combating misinformation and restoring public trust in vaccines. The persistent threat of misinformation necessitates proactive communication strategies and community engagement to reinforce the importance of vaccination in safeguarding public health.

Additionally, the emergence of new variants and strains of viruses poses a potential threat to the efficacy of existing vaccines. As pathogens evolve, there is a risk that current vaccines may not provide adequate protection, necessitating the development of new formulations or boosters. The need for continuous research and surveillance is crucial to adapt vaccine strategies in response to evolving public health challenges. Furthermore, logistical challenges associated with vaccine distribution, particularly in low-resource settings, remain a barrier to ensuring equitable access to MMR vaccinations globally. Addressing these threats requires coordinated efforts among governments, healthcare providers, and public health organizations to maintain robust vaccination programs and adaptability to emerging challenges.

Competitor Outlook

• Merck & Co., Inc.
• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Pfizer Inc.
• AbbVie Inc.
• Novartis AG
• CSL Limited
• Hoffmann-La Roche AG
• Emergent BioSolutions Inc.
• MedImmune LLC
• Serum Institute of India Pvt. Ltd.
• China National Pharmaceutical Group (Sinopharm)
• Instituto Butantan
• Takeda Pharmaceutical Company Limited
• BioNTech SE

The competitive landscape of the MMR vaccines market is characterized by a mix of established multinational corporations and emerging biotechnology firms. Major players like Merck & Co., Inc. and Sanofi Pasteur dominate the market, leveraging their extensive research and development capabilities, established distribution networks, and strong brand recognition. These companies invest significantly in ongoing research to innovate and improve vaccine formulations, ensuring they remain at the forefront of vaccine technology. Furthermore, they often collaborate with governmental organizations and international health agencies to enhance vaccine accessibility and awareness, particularly in underserved regions.

Emerging companies and biotechnology firms are also gaining a foothold in the MMR vaccines market, driven by the need for innovative solutions in vaccine delivery and formulation. These players are focusing on developing next-generation vaccines that utilize novel technologies, such as mRNA platforms or alternative delivery methods. Their agility and focus on niche markets may provide them with a competitive advantage in addressing specific public health needs or geographical challenges. The ongoing collaboration between established pharmaceutical giants and these emerging entities fosters an environment of innovation and progress in the MMR vaccines market, contributing to a robust competitive landscape.

Key companies such as GlaxoSmithKline and Pfizer Inc. are also heavily involved in public health initiatives aimed at increasing vaccination rates and awareness. Their commitment to corporate social responsibility often leads to partnerships with non-profit organizations and health agencies to support immunization programs, especially in developing countries. This not only enhances their brand reputation but also positions them as leaders in global health efforts to eradicate measles, mumps, and rubella. By aligning their business goals with public health priorities, these companies contribute to the overall growth and success of the MMR vaccines market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 BioNTech SE
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 CSL Limited
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 MedImmune LLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi Pasteur
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Instituto Butantan
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hoffmann-La Roche AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline (GSK)
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Emergent BioSolutions Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Serum Institute of India Pvt. Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 China National Pharmaceutical Group (Sinopharm)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 MMR Vaccines Market, By Application
    • 6.1.1 Pediatrics
    • 6.1.2 Adults
    • 6.1.3 Travelers
    • 6.1.4 Healthcare Workers
    • 6.1.5 Others
  • 6.2 MMR Vaccines Market, By Product Type
    • 6.2.1 Measles-Mumps-Rubella Vaccine
    • 6.2.2 Measles-Rubella Vaccine
    • 6.2.3 Measles-Mumps Vaccine
    • 6.2.4 Mumps-Rubella Vaccine
    • 6.2.5 Others
  • 6.3 MMR Vaccines Market, By Ingredient Type
    • 6.3.1 Live Attenuated Virus
    • 6.3.2 Excipients
    • 6.3.3 Preservatives
    • 6.3.4 Stabilizers
    • 6.3.5 Others
  • 6.4 MMR Vaccines Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 MMR Vaccines Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global MMR Vaccines market is categorized based on

By Product Type

• Measles-Mumps-Rubella Vaccine
• Measles-Rubella Vaccine
• Measles-Mumps Vaccine
• Mumps-Rubella Vaccine
• Others

By Application

• Pediatrics
• Adults
• Travelers
• Healthcare Workers
• Others

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Live Attenuated Virus
• Excipients
• Preservatives
• Stabilizers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Merck & Co., Inc.
• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Pfizer Inc.
• AbbVie Inc.
• Novartis AG
• CSL Limited
• Hoffmann-La Roche AG
• Emergent BioSolutions Inc.
• MedImmune LLC
• Serum Institute of India Pvt. Ltd.
• China National Pharmaceutical Group (Sinopharm)
• Instituto Butantan
• Takeda Pharmaceutical Company Limited
• BioNTech SE